GSK Steps Up Parkinson’s Focus With US Biotech Deal

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug development for Parkinson’s disease.

GSK will pay $80 million upfront and as much as $570 million to gain full development and commercialization rights to Vesalius’s early-stage drug program that has an initial focus on the degenerative brain condition.

Vesalius, founded by venture capital firm Flagship Pioneering, has a platform that uses AI, genomics and other models to identify new ways to treat diseases. It can create human avatars with different disease characteristics that can be used in ...